XBIOTECH INC. Revenue from Contract with Customer, Including Assessed Tax
XBIOTECH INC. (XBIT) reported Revenue from Contract with Customer, Including Assessed Tax of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-15.
Discontinued › Income Statement
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax · last filed 2024-03-15
- XBIOTECH INC. revenue from contract with customer, including assessed tax for the quarter ending 2023-12-31 was $0.00, a 100.00% decline year-over-year.
- XBIOTECH INC. revenue from contract with customer, including assessed tax for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- XBIOTECH INC. revenue from contract with customer, including assessed tax for the quarter ending 2023-06-30 was $0.00, a 100.00% decline year-over-year.
- XBIOTECH INC. revenue from contract with customer, including assessed tax for the quarter ending 2023-03-31 was $0.00, a 100.00% decline year-over-year.
- XBIOTECH INC. revenue from contract with customer, including assessed tax for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- XBIOTECH INC. revenue from contract with customer, including assessed tax for fiscal 2022 was $4.01M, a 78.20% decline from fiscal 2021.
- XBIOTECH INC. revenue from contract with customer, including assessed tax for fiscal 2021 was $18.39M, a 58.19% decline from fiscal 2020.
- XBIOTECH INC. revenue from contract with customer, including assessed tax for fiscal 2020 was $44.00M.
| Period end | Revenue from Contract with Customer, Including Assessed Tax 3 month | Revenue from Contract with Customer, Including Assessed Tax 6 month | Revenue from Contract with Customer, Including Assessed Tax 9 month | Revenue from Contract with Customer, Including Assessed Tax 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $0.00 derived: sum of 2 quarters · filed 2024-03-15 | $0.00 derived: sum of 3 quarters · filed 2024-03-15 | $0.00 10-K · filed 2024-03-15 |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-09 | $0.00 derived: sum of 2 quarters · filed 2023-11-09 | $0.00 10-Q · filed 2023-11-09 | $300.00K derived: sum of 4 quarters · filed 2024-03-15 |
| 2023-06-30 | $0.00 10-Q · filed 2023-08-11 | $0.00 10-Q · filed 2023-08-11 | $300.00K derived: sum of 3 quarters · filed 2024-03-15 | $1.98M derived: sum of 4 quarters · filed 2024-03-15 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-10 | $300.00K derived: sum of 2 quarters · filed 2024-03-15 | $1.98M derived: sum of 3 quarters · filed 2024-03-15 | $3.51M derived: sum of 4 quarters · filed 2024-03-15 |
| 2022-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $1.98M derived: sum of 2 quarters · filed 2024-03-15 | $3.51M derived: sum of 3 quarters · filed 2024-03-15 | $4.01M 10-K · filed 2024-03-15 |
| 2022-09-30 | $1.68M 10-Q · filed 2023-11-09 | $3.21M derived: sum of 2 quarters · filed 2023-11-09 | $3.71M 10-Q · filed 2023-11-09 | $8.21M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $1.53M 10-Q · filed 2023-08-11 | $2.03M 10-Q · filed 2023-08-11 | $6.53M derived: sum of 3 quarters · filed 2023-08-11 | $11.05M derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | $500.00K 10-Q · filed 2023-05-10 | $5.00M derived: sum of 2 quarters · filed 2023-05-10 | $9.52M derived: sum of 3 quarters · filed 2023-05-10 | $14.04M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $4.50M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $9.02M derived: sum of 2 quarters · filed 2023-03-15 | $13.54M derived: sum of 3 quarters · filed 2023-03-15 | $18.39M 10-K · filed 2023-03-15 |
| 2021-09-30 | $4.52M 10-Q · filed 2022-11-09 | $9.04M derived: sum of 2 quarters · filed 2022-11-09 | $13.89M 10-Q · filed 2022-11-09 | $19.16M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $4.53M 10-Q · filed 2022-08-10 | $9.38M 10-Q · filed 2022-08-10 | $14.64M derived: sum of 3 quarters · filed 2022-08-10 | $25.19M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $4.85M 10-Q · filed 2022-05-10 | $10.12M derived: sum of 2 quarters · filed 2022-05-10 | $20.67M derived: sum of 3 quarters · filed 2022-05-10 | $36.17M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $5.27M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $15.82M derived: sum of 2 quarters · filed 2022-03-15 | $31.32M derived: sum of 3 quarters · filed 2022-03-15 | $44.00M 10-K · filed 2022-03-15 |
| 2020-09-30 | $10.55M 10-Q · filed 2021-11-09 | $26.05M derived: sum of 2 quarters · filed 2021-11-09 | $38.73M 10-Q · filed 2021-11-09 | $38.73M derived: sum of 4 quarters · filed 2022-03-15 |
| 2020-06-30 | $15.50M 10-Q · filed 2021-08-09 | $28.18M 10-Q · filed 2021-08-09 | $28.18M derived: sum of 3 quarters · filed 2022-03-15 | $28.18M derived: sum of 4 quarters · filed 2022-03-15 |
| 2020-03-31 | $12.68M 10-Q · filed 2021-05-10 | $12.68M derived: sum of 2 quarters · filed 2022-03-15 | $12.68M derived: sum of 3 quarters · filed 2022-03-15 | $12.68M derived: sum of 4 quarters · filed 2022-03-15 |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $0.00 derived: sum of 2 quarters · filed 2022-03-15 | $0.00 derived: sum of 3 quarters · filed 2022-03-15 | $0.00 10-K · filed 2022-03-15 |
| 2019-09-30 | $0.00 10-Q · filed 2020-11-09 | $0.00 derived: sum of 2 quarters · filed 2020-11-09 | $0.00 10-Q · filed 2020-11-09 | |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $0.00 10-Q · filed 2020-08-10 | ||
| 2019-03-31 | $0.00 10-Q · filed 2020-05-11 | |||
| 2018-12-31 | $0.00 10-K · filed 2021-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |